IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announces today the nomination of Suzette Kox as Secretary General of the association. Her main role is to coordinate the IGBA activities as IGBA continues to expand its outreach relevant to its mission, priorities and operations.
The International Generic and Biosimilar Medicines Association (IGBA) strengthens cooperation between associations who represent manufacturers of generic and biosimilar medicines from around the world. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients around the world have access to high quality, pro-competitive medicines. IGBA’s full-members include the Canadian Generic Pharmaceutical Association, Medicines for Europe, the Association for Accessible Medicines (USA), Japan Generic Medicines Association, Jordanian Association of Pharmaceutical Manufacturers, Indian Pharmaceutical Alliance, Generic & Biosimilar Medicines Southern Africa, and Taiwan Generic Pharmaceutical Association.
IGBA proposes a new international biosimilars framework allowing bridging studies to be waived in specific circumstances based on core scientific and regulatory principles established for current products.
